S&P 500   3,632.67 (+1.54%)
DOW   30,069.46 (+1.62%)
QQQ   293.33 (+1.01%)
AAPL   114.66 (+0.71%)
MSFT   213.07 (+1.41%)
FB   274.09 (+2.11%)
GOOGL   1,751.78 (+1.40%)
AMZN   3,117.90 (+0.63%)
TSLA   547.00 (+4.82%)
NVDA   518.71 (-1.31%)
BABA   276.63 (+2.41%)
CGC   26.81 (+8.45%)
GE   10.56 (+4.87%)
MU   63.17 (-1.57%)
AMD   84.79 (-0.61%)
T   29.27 (+2.27%)
NIO   53.38 (-3.61%)
F   9.41 (+6.21%)
ACB   9.07 (+26.32%)
NFLX   480.99 (+0.92%)
GILD   60.72 (+1.39%)
BA   221.23 (+4.59%)
DIS   151.15 (+3.54%)
S&P 500   3,632.67 (+1.54%)
DOW   30,069.46 (+1.62%)
QQQ   293.33 (+1.01%)
AAPL   114.66 (+0.71%)
MSFT   213.07 (+1.41%)
FB   274.09 (+2.11%)
GOOGL   1,751.78 (+1.40%)
AMZN   3,117.90 (+0.63%)
TSLA   547.00 (+4.82%)
NVDA   518.71 (-1.31%)
BABA   276.63 (+2.41%)
CGC   26.81 (+8.45%)
GE   10.56 (+4.87%)
MU   63.17 (-1.57%)
AMD   84.79 (-0.61%)
T   29.27 (+2.27%)
NIO   53.38 (-3.61%)
F   9.41 (+6.21%)
ACB   9.07 (+26.32%)
NFLX   480.99 (+0.92%)
GILD   60.72 (+1.39%)
BA   221.23 (+4.59%)
DIS   151.15 (+3.54%)
S&P 500   3,632.67 (+1.54%)
DOW   30,069.46 (+1.62%)
QQQ   293.33 (+1.01%)
AAPL   114.66 (+0.71%)
MSFT   213.07 (+1.41%)
FB   274.09 (+2.11%)
GOOGL   1,751.78 (+1.40%)
AMZN   3,117.90 (+0.63%)
TSLA   547.00 (+4.82%)
NVDA   518.71 (-1.31%)
BABA   276.63 (+2.41%)
CGC   26.81 (+8.45%)
GE   10.56 (+4.87%)
MU   63.17 (-1.57%)
AMD   84.79 (-0.61%)
T   29.27 (+2.27%)
NIO   53.38 (-3.61%)
F   9.41 (+6.21%)
ACB   9.07 (+26.32%)
NFLX   480.99 (+0.92%)
GILD   60.72 (+1.39%)
BA   221.23 (+4.59%)
DIS   151.15 (+3.54%)
S&P 500   3,632.67 (+1.54%)
DOW   30,069.46 (+1.62%)
QQQ   293.33 (+1.01%)
AAPL   114.66 (+0.71%)
MSFT   213.07 (+1.41%)
FB   274.09 (+2.11%)
GOOGL   1,751.78 (+1.40%)
AMZN   3,117.90 (+0.63%)
TSLA   547.00 (+4.82%)
NVDA   518.71 (-1.31%)
BABA   276.63 (+2.41%)
CGC   26.81 (+8.45%)
GE   10.56 (+4.87%)
MU   63.17 (-1.57%)
AMD   84.79 (-0.61%)
T   29.27 (+2.27%)
NIO   53.38 (-3.61%)
F   9.41 (+6.21%)
ACB   9.07 (+26.32%)
NFLX   480.99 (+0.92%)
GILD   60.72 (+1.39%)
BA   221.23 (+4.59%)
DIS   151.15 (+3.54%)
Log in
OTCMKTS:ZLDPF

Zealand Pharma A/S Stock Forecast, Price & News

$35.95
-0.05 (-0.14 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$35.95
Now: $35.95
$35.99
50-Day Range
$33.40
MA: $37.65
$43.05
52-Week Range
$24.60
Now: $35.95
$43.05
Volume700 shs
Average Volume1,712 shs
Market Capitalization$1.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.65
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Read More
Zealand Pharma A/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ZLDPF
Previous SymbolNASDAQ:ZLDPF
CUSIPN/A
CIKN/A
Phone45-8877-3600
Employees313

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.20 million
Book Value$5.20 per share

Profitability

Net Income$-85,670,000.00
Net Margins-296.37%

Miscellaneous

Market Cap$1.29 billion
Next Earnings Date11/26/2020 (Estimated)
OptionableNot Optionable
$35.95
-0.05 (-0.14 %)
(As of 11/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZLDPF News and Ratings via Email

Sign-up to receive the latest news and ratings for ZLDPF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zealand Pharma A/S (OTCMKTS:ZLDPF) Frequently Asked Questions

How has Zealand Pharma A/S's stock been impacted by Coronavirus (COVID-19)?

Zealand Pharma A/S's stock was trading at $37.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ZLDPF stock has decreased by 5.0% and is now trading at $35.95.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Zealand Pharma A/S?

Wall Street analysts have given Zealand Pharma A/S a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zealand Pharma A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zealand Pharma A/S's next earnings date?

Zealand Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, November 26th 2020.
View our earnings forecast for Zealand Pharma A/S
.

Are investors shorting Zealand Pharma A/S?

Zealand Pharma A/S saw a decline in short interest in October. As of October 15th, there was short interest totaling 53,900 shares, a decline of 17.3% from the September 30th total of 65,200 shares. Based on an average daily volume of 300 shares, the days-to-cover ratio is currently 179.7 days.
View Zealand Pharma A/S's Short Interest
.

Who are some of Zealand Pharma A/S's key competitors?

Who are Zealand Pharma A/S's key executives?

Zealand Pharma A/S's management team includes the following people:
  • Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBA, CEO & Pres (Age 51)
  • Mr. Matthew Donald Dallas, Sr. VP & CFO (Age 45)
  • Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Representative Director (Age 67)
  • Mr. Adam Sinding Steensberg M.D., Exec. VP of R&D and Chief Medical Officer (Age 46)
  • Mr. Ivan Mourits Møller, Sr. VP of Technical Devel. & Operations (Age 48)
  • Rie Schultz Hansen, Interim Chief Scientific Officer & VP of Research
  • Lani Pollworth Morvan, Investor Relations & Communications Officer
  • Mr. Mads Kronborg, Head of Investor Relations & Communication
  • Søren Vitfell Keller, Head of Legal Affairs
  • Mr. Marino Garcia M.B.A., Sr. VP of Corp. & Bus. Devel. (Age 54)

What is Zealand Pharma A/S's stock symbol?

Zealand Pharma A/S trades on the OTCMKTS under the ticker symbol "ZLDPF."

How do I buy shares of Zealand Pharma A/S?

Shares of ZLDPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zealand Pharma A/S's stock price today?

One share of ZLDPF stock can currently be purchased for approximately $35.95.

How big of a company is Zealand Pharma A/S?

Zealand Pharma A/S has a market capitalization of $1.29 billion and generates $6.20 million in revenue each year. Zealand Pharma A/S employs 313 workers across the globe.

What is Zealand Pharma A/S's official website?

The official website for Zealand Pharma A/S is www.zealandpharma.com.

How can I contact Zealand Pharma A/S?

Zealand Pharma A/S's mailing address is Sydmarken 11 Soborg, Copenhagen G7, 2860. The company can be reached via phone at 45-8877-3600 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.